Journal of investigational allergology & clinical immunology最新文献

{"title":"COVID-19 and TEN Treated With IVIG and Total Plasma Exchange: Simultaneous Systemic Treatment for Both Diseases.","authors":"A Krajewski, E Mlynska-Krajewska, K Kaczynska, J Strużyna, M J Mazurek","doi":"10.18176/jiaci.0692","DOIUrl":"https://doi.org/10.18176/jiaci.0692","url":null,"abstract":"","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"522-523"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25583934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large Local Reactions to Hymenoptera Stings Negatively Affect Quality of Life to the Same Degree as Systemic Reactions.","authors":"L Sánchez-Morillas, T Alfaya Arias, M Martínez San Ireneo, C Domínguez Noche, J M Vega Gutierrez, A Vega Castro, E Moreno Mata, L Marqués, M Fuentes Ferrer, B Ruiz-León","doi":"10.18176/jiaci.0688","DOIUrl":"https://doi.org/10.18176/jiaci.0688","url":null,"abstract":"5. Larsen PL, Tos M. Origin of nasal polyps: an endoscopic autopsy study. Laryngoscope. 2004;114:710-9. 6. Klossek JM, Neukirch F, Pribil C, Jankowski R, Serrano E, Chanal I, et al. Prevalence of nasal polyposis in France: a cross-sectional, case-control study. Allergy. 2005;60(2):2337. 7. Bachert C, Marple B, Hosemann W, Cavaliere C, Wen W, Zhang N. Endotypes of Chronic Rhinosinusitis with Nasal Polyps: Pathology and Possible Therapeutic Implications. J Allergy Clin Immunol Pract. 2020;8(5):1514-9. 8. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127:550-5. 9. Lobo DR, López-Cortijo C, Laguna D, Pinilla M, Górriz C. Endoscopic sinonasal surgery: Review of 1,093 cases. Acta Otorrinolaringológica Española. 2003;54(6), 435-40. 10. Brescia G, Sfriso P, Marioni G. Role of inflammatory cells in chronic rhinosinusitis with nasal polyps. Acta OtoLaryngologica. 2019;139(1):48-51. 11. Guo M, Alasousi F , Okpaleke C , Habib AR, Javer A. Prognosis of Chronic Rhinosinusitis With Nasal Polyps Using Preoperative Eosinophil/Basophil Levels and Treatment Compliance. Am J Rhinol Allergy. 2018;32(5):440-6. Large Local Reactions to Hymenoptera Stings Negatively Affect Quality of Life to the Same Degree as Systemic Reactions","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"502-504"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25479713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immediate-Type Hypersensitivity to Polyethylene Glycol (PEG) and a PEG-Containing COVID-19 Vaccine Revealed by Intradermal Testing.","authors":"J Pickert, I Hennighausen, S Mühlenbein, C Möbs, W Pfützner","doi":"10.18176/jiaci.0720","DOIUrl":"https://doi.org/10.18176/jiaci.0720","url":null,"abstract":"","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"526-527"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39241056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Referral Criteria for Asthma and the Pandemic: New Challenges, New Responses.","authors":"J Delgado Romero, S Núñez Palomo, A M Uréndez Ruiz, F Gómez Ruiz, A Hidalgo Requena, F J Álvarez Gutiérrez","doi":"10.18176/jiaci.0747","DOIUrl":"https://doi.org/10.18176/jiaci.0747","url":null,"abstract":"UGC Alergología. Hospital Virgen Macarena. Sevilla. Sociedad Española de Alergología e Inmunología Clínica (SEAIC). CS Torrelaguna. Madrid. Sociedad Española de Medicina Familiar y Comunitaria (semFYC). Urgencias de Atención Primaria, SAMU 061 Balears. Grupo de Respiratorio en Atención Primaria (GRAP). CS Bargas. Toledo. Sociedad Española de Médicos Generales y de Familia (SEMG). UGC Lucena. Área Sanitaria Sur de Córdoba. Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Unidad de Asma. UMQER. Hospital Universitario Virgen del Rocío. Sevilla. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"530-532"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39392465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Desensitization to Daratumumab After a Severe Life-threatening Reaction in a Patient With Refractory Multiple Myeloma.","authors":"A Carrón-Herrero, E Solano-Solares, C Geraldine Rita, E Rodríguez-Martín, A Ruedas, I Barbolla, M P Berges-Gimeno","doi":"10.18176/jiaci.0678","DOIUrl":"https://doi.org/10.18176/jiaci.0678","url":null,"abstract":"dexchlorpheniramine (5 mg), and intramuscular epinephrine (0.5 mg) were administered. Nevertheless, the patient’s symptoms progressed, with right oculocephalic deviation, lack of glabellar and menace reflexes, and hypercapnic respiratory acidosis. Therefore, she was admitted to the intensive care unit, where invasive mechanical ventilation and a norepinephrine perfusion were started. The patient’s condition stabilized, and she was successfully extubated after 2 days without neurological sequelae. No tryptase levels were measured. A grade 4 IRR [2] was diagnosed, and the patient was referred to our allergy department. Skin tests with daratumumab (skin prick test at concentrations of 20 mg/mL, 2 mg/mL, and 0.2 mg/mL and an intradermal test at concentrations of 2 mg/mL and 0.2 mg/mL) performed 3 weeks after the reaction yielded negative results [3]. Baseline tryptase was 3.41 ng/mL (normal, <11.5 ng/mL). A basophil activation test (BAT) to daratumumab was performed at different concentrations (0.5 mg/mL, 1 mg/mL, and 2 mg/mL) using the 2 most common markers of activation/degranulation (CD203c and CD63) [4], with negative results for all the concentrations tested. The referring physicians confirmed that daratumumab was the best therapeutic option owing to disease progression and failure of first-line therapy. We assessed the risks for management, and the informed consent was signed. Based on risk stratification for the severe reaction, a 4-bag, 14-step rapid drug desensitization (RDD) protocol was administered [5]. Additional premedication was with montelukast and aspirin, and no breakthrough reactions were recorded (Table). IL-6 levels were measured using high-sensitivity single-molecule array (Simoa) technology [6], which reduces IL-6 levels after desensitization (baseline, 21.85 pg/mL; after desensitization, <2 pg/mL). To date, the patient has tolerated 15 cycles without incident. Disease control is excellent. Hypersensitivity reactions to monoclonal antibodies include infusion-related reactions, cytokine-release reactions (CRRs), type 1 reactions (IgE/non-IgE), type 3 reactions (immune complexes), and delayed type 4 reactions [3]. IRRs and CRRs to monoclonal antibodies can occur at the first infusion. In most cases, the difference between IRRs and CRRs is the self-limiting nature of IRRs on repeat exposure and the response to premedication [5]. Although the patient received premedication according to the summary of product characteristics of daratumumab, she developed a severe lifethreatening reaction. No IgE-mediated hypersensitivity reactions to daratumumab have been reported to date. Polysorbate 20 and mannitol are excipients of daratumumab. Cases of anaphylaxis due to sensitization to mannitol and polysorbate (mainly polysorbate 80) have been reported [7,8]. Since no IgE-mediated mechanism was demonstrated in the present case following skin tests and BAT, and given that the patient developed a severe life-threatening reaction despite receivin","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"511-513"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25332214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophilic Generalized Fixed Drug Eruption Induced by Etoricoxib.","authors":"A Vera, A Freih, M V Múgica, F Vega, M T Belver, C Blanco","doi":"10.18176/jiaci.0687","DOIUrl":"https://doi.org/10.18176/jiaci.0687","url":null,"abstract":"1. Andersen KE, Hjorth N, Menné T. The baboon syndrome: systemically-induced allergic contact dermatitis. Contact Derm. 1984;10:97. 2. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004;51(5-6):297-310. 3. Winnicki M, Shear NH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol. 2011;12(3):171-80. 4. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, et al; ENDA; EAACI. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy. 2004;59(11):1153-60. 5. Pineda R, Rojas P, Martínez P, Zambrano G, Morales C, de Barrio M. Erythrodysestesia-like skin eruption due to docetaxel with a nonimmediate positive intradermal skin test result. J Allergy Clin Immunol Pract. 2016;4(2):341-2.","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"517-519"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25479712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypersensitivity to Covid-19 Vaccine Confirmed by a Positive Skin Test Result: A Case Report.","authors":"S Pérez-Codesido, A Rosado, M D Alonso-Díaz-de-Durana, T Alfaya Arias, A González-Moreno, M A Tejedor Alonso","doi":"10.18176/jiaci.0718","DOIUrl":"https://doi.org/10.18176/jiaci.0718","url":null,"abstract":"","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"524-525"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39088650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis.","authors":"N Freemantle, C Piketty","doi":"10.18176/jiaci.0727","DOIUrl":"https://doi.org/10.18176/jiaci.0727","url":null,"abstract":"To the Editor: We were interested to read the meta-analysis by Xuemin et al [1] on the efficacy and safety of nemolizumab for treatment of adult atopic dermatitis. This is an important area, and an overview of the available data is timely. We concur with the conclusions of the authors that nemolizumab is a promising treatment, and Galderma is currently undertaking further phase 3 clinical trials to gather new data. On one important point, however, we struggle to reconcile the results and conclusions of the review with our knowledge of the published data. The authors comment that the 60-mg Q4w regimen is likely to be optimal. The only complete phase 3 trial that has compared that dose [2] on a proper likefor-like basis with a lower dose currently in late development (30 mg Q4w) is actually in favor of the lower dose. The percent change in the Eczema Area and Severity Index (EASI) (from baseline to week 16) for the 30-mg Q4w dose vs placebo (difference, –23.7; 95%CI, –8.9 to –38.5; P=.002) was reported in the phase 2b trial of Silverberg et al [3]. The treatment effect observed with EASI was greater than that observed with the 60-mg Q4w dose in the phase 3 trial by Kabashima et al [2] (difference, –12.6; 95%CI, –1.3 to –24.0). Using the method of Bucher et al [4] to undertake a formal indirect comparison, we observed a numerically greater benefit for 30 mg Q4w (difference, –11.1; 95%CI, 7.6 to –29.8) (Figure). The 30-mg dose is under evaluation in 2 pivotal phase 3 trials (NCT03989349 and NCT03985943), and analysis of the outcomes of both will help us resolve this important question. We do not recognize some of the data included by the reviewers in their work; for example, the results above for Silverberg et al [3] derived from the clinical study report are not reflected in the report by Xuemin et al [1]. This is troubling. While the overall conclusions are supported by individual trials, the dosage conclusions do not reflect current data.","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"528-529"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39143113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.","authors":"A Matito,&nbsp;M M Escribese,&nbsp;N Longo,&nbsp;C Mayorga,&nbsp;O Luengo-Sánchez,&nbsp;M Pérez-Gordo,&nbsp;V Matheu,&nbsp;M Labrador-Horrillo,&nbsp;M Pascal,&nbsp;M E Seoane-Reula","doi":"10.18176/jiaci.0675","DOIUrl":"https://doi.org/10.18176/jiaci.0675","url":null,"abstract":"<p><p>The diagnosis of mast cell activation syndrome (MCAS) is defined by 3 criteria: (1) typical clinical signs and symptoms of acute, recurrent (episodic), and systemic mast cell activation (MCA); (2) increase in tryptase level to >20% + 2 ng/mL within 1-4 hours after onset of the acute crisis; and (3) response of MCA symptoms to antimediator therapy. Classification of MCAS requires highly sensitive and specific methodological approaches for the assessment of clonal bone marrow mast cells at low frequencies. The Spanish Network on Mastocytosis score has been used successfully as a predictive model for selecting MCAS candidates for bone marrow studies based on a high probability of an underlying clonal mast cell disorder. In this article, we propose a diagnostic algorithm and focus on the practical evaluation and management of patients with suspected MCAS.</p>","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"461-470"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25332215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual Secretion of Eosinophil Mediators Induced by Benralizumab.","authors":"J A Cañas,&nbsp;M Valverde-Monge,&nbsp;M Rodríguez-Nieto,&nbsp;N González-Mangado,&nbsp;J Sastre,&nbsp;V Del Pozo","doi":"10.18176/jiaci.0684","DOIUrl":"https://doi.org/10.18176/jiaci.0684","url":null,"abstract":"2. Cmelak AJ, Lordick F, Borner MM, Goldberg RM, Wasif Saif M. Management of Infusion Reactions in Clinical Trials and Beyond: The US and EU Perspectives. Oncology. 2009;23:1825. 3. Isabwe GAC, Carcia M, de Las Vecillas L, Lynch DM, Marquis K, Castells MC. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. J Allergy Clin Immunol. 2018;142:159-70. 4. Thévenot J, Ferrier le Bouëdec MC, Buisson A, Bommelaer G, D'Incan M, Rouzaire P. Rapid Desensitization to Adalimumab Is Associated With Decreased Basophil Sensitivity. J Investig Allergol Clin Immunol. 2019;29(2):141-3. 5. Madrigal R, Bernal L, Berges MP, Carpio LV, Gehlhaar P, Alvarez E. A Large Single-Hospital Experience Using Drug Provocation Testing and Rapid Drug Desensitization in Hypersensitivity to Antineoplastic and Biological Agents. J Allergy Clin Immunol Pract. 2019;7:618-32. 6. Yeung D, Ciotti S, Purushothama S, Gharakhani E, Kuesters G, Schlain B, et al. Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serum. J Immunol Methods. 2016;437:53‐63. 7. Hegde VL, Venkatesh YP. Anaphylaxis to excipient mannitol: evidence for an immunoglobulin E-mediated mechanism. Clin Exp Allergy. 2004;34:1602-9. 8. Badiu I, Geuna M, Heffler E, Rolla G. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ Case Rep. 2012 May 8;2012:bcr0220125797. 9. De Lira Quezada CE, Villarreal González RV, González Díaz SN, Acuña Ortega N. Protocol for Desensitization to Trastuzumab in a Patient With Anaphylaxis and Stage IV Breast Cancer: A Case Report. J Investig Allergol Clin Immunol. 2020;30(5):3767. 10. Sancho-Serra Mdel C, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. Eur J Immunol. 2011;41(4):1004-13.","PeriodicalId":520676,"journal":{"name":"Journal of investigational allergology & clinical immunology","volume":" ","pages":"513-515"},"PeriodicalIF":7.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25420694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}